Earnings call transcripts

Management framed the quarter as broad-based execution, with raised 2026 guidance and investment-driven momentum extending into 2027. 2026 guidance increased despite a $71 million reserve-development headwind.

Management framed the turnaround as gaining operational traction, while cautioning that traffic recovery will lag improving guest metrics.

Management framed the quarter as proof that Aetna recovery and retail execution are broadening enterprise momentum, while flagging preliminary 2027 PBM pressures.

Management framed Q2 as proof that product execution and cost restructuring can drive growth despite weak luxury demand and sharply lower marketing spend.

Management framed the quarter as proof that innovation and omnichannel execution are overcoming veterinary-visit pressure while accelerating deleveraging and margins.

Management framed the quarter as resilient execution, while lowering the growth outlook to account for persistent Middle East travel disruption and emphasizing integration progress.

Management framed the quarter as broad-based, volume-led progress, while emphasizing divestiture execution, cost removal and prudent guidance amid uncertain markets.

Management framed the quarter as steady execution, with VCP adoption building despite elongated enterprise buying cycles and delayed restaurant hardware refreshes.

Management framed the quarter as strong demand masking a Type 2 onboarding and retention execution issue requiring revised expectations.

Management framed the call around a sharper, multi-year pivot toward fewer markets, category leadership, capital-light growth and tighter execution.

Management framed the quarter as evidence of durable growth and disciplined capital allocation, while emphasizing an expanding pipeline and increased 2026 guidance.

Management framed the quarter as evidence that audience growth is translating into leverage while investments position Uber to commercialize AVs at scale.